Pharmacokinetics and metabolism update for some recent antipsychotics

Bibliography

• Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Pysichiatry 2003;27(7):1159-72
   PubMed Web of Science ®Google Scholar
• Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work-from receptors to reality. Neurorx 2006;3(1):10-21
   PubMedGoogle Scholar
• Barnes TR, Mcphillips MA. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics. Br J Psychiatry 1999;38 (Suppl):34-43
   Google Scholar
• Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995;15(Suppl 1):4S-10S
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28(3):519-26
   PubMed Web of Science ®Google Scholar
• Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19(6 Suppl):16-27
   PubMedGoogle Scholar
• Dorado P, Berecz R, Penas-Lledo EM, Llerena A. Antipsychotic drugs and Qtc prolongation: the potential role of cyp2d6 genetic polymorphism. Expert Opin Drug Metab Toxicol 2007;3(1):9-19
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, ; For the clinical antipsychotic trials of intervention effectiveness (CATIE) investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-87
   PubMed Web of Science ®Google Scholar
• Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 2009;23(8):649-59
   PubMed Web of Science ®Google Scholar
• Foussias G, Remington G. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making. Can J Psychiatry 2010;55(3):117-25
   PubMed Web of Science ®Google Scholar
• Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64(15):1715-36
   PubMed Web of Science ®Google Scholar
• Urban JD, Vargas GA, von Zastrow M, Mailman RB. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007;32(1):67-77
   PubMed Web of Science ®Google Scholar
• Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des 2010;16(5):488-501
   PubMed Web of Science ®Google Scholar
• Jones CA, McCreary AC. Serotonergic approaches in the development of novel antipsychotics. Neuropharmacology 2008;55(6):1056-65
   PubMed Web of Science ®Google Scholar
• Terry AV Jr, Buccafusco JJ, Wilson C. Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 2008;195(1):30-8
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Sumiyoshi T. Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia? Behav Brain Res 2008;195(1):98-102
   PubMed Web of Science ®Google Scholar
• El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2006;2:CD004578
   PubMedGoogle Scholar
• Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2008;3:CD006617
   PubMedGoogle Scholar
• Kato T, Hirose A, Ohno Y, Binding profile of SM-9018, a novel antipsychotic candidate. Jpn J Pharmacol 1990;54(4):478-81
   PubMedGoogle Scholar
• Shiwa T, Amano T, Matsubayashi H, Perospirone, a novel antipsychotic agent, hyperpolarizes rat dorsal raphe neurons via 5-HT1A receptor. J Pharmacol Sci 2003;93:114-17
   PubMed Web of Science ®Google Scholar
• Araki T, Yamasue H, Sumiyoshi T, Perospirone in the treatment of schizophrenia: effect on verbal memory organization. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(2):204-8
   PubMed Web of Science ®Google Scholar
• de Paulis T. Perospirone (Sumitomo Pharmaceuticals). Curr Opin Investig Drugs 2002;3(1):121-9
   PubMedGoogle Scholar
• Onrust SV, McClellan K. Perospirone. CNS Drugs 2001;15(4):329-37
   PubMed Web of Science ®Google Scholar
• Okugawa G, Kato M, Wakeno M, Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study. Psychiatry Clin Neurosci 2009;63(3):322-8
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Horisawa T, Tokuda K, Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther 2010;334(1):171-81
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ogasa M, Guarino J, Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(6):829-36
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Ogasa M, Efficacy of lurasidone: summary of results from the clinical development program. Int J Neuropsychopharmacol 2010;70(6):227-8
   Google Scholar
• Harwey PD, Murasaki M, Cucchiaro J, A three arm dose finding study of lurasidone; efficacy and tolerability data. Schizophr Res 2010;117:2-3 (374-375)
   Google Scholar
• Cucchiaro J, Pikalow A, Ogasa M, Safety of lurasidone: pooled analysis of five placebo-controlled trials in patients with schizophrenia. Int J Neuropsychopharmacol 2010;13(Suppl. S1): abstract P-20.021, 217
   Web of Science ®Google Scholar
• Bose A, Li D, Migliore R, The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Int J Neuropsychopharmacol 2010; abstract P-04.012, 88
   Web of Science ®Google Scholar
• Knesevich MA, Papadakis K, Bose A, The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord 2009;11:s1 (54)
   Google Scholar
• Kiss B, Horvath A, Nemethy Z, Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010;333(1):328-40
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A, Cussac D, Depoortere R. Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007;8(7):539-54
   PubMed Web of Science ®Google Scholar
• Newman-Tancredi A. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs 2010;11(7):802-12
   PubMed Web of Science ®Google Scholar
• Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 2010;32(Suppl 1):S3-20
   PubMedGoogle Scholar
• Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18(11):1715-26
   PubMed Web of Science ®Google Scholar
• Grunder G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr Opin Investig Drugs 2010;11(7):823-32
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drug Approval Package. Latuda (lurasidone hydrochloride) Tablets. Sunovion Pharmaceuticals, Inc. Clinical Review; Pharmacology Review(s); Clinical Pharmacology Biopharmaceutics Review(s). Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Drug-Details [Last accessed November 2010]
   Google Scholar
• Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996;57(Suppl 11):12-25
   PubMedGoogle Scholar
• Sheehan JJ, Sliwa JK, Amatniek JC, Atypical antipsychotic metabolism and excretion. Curr Drug Metab 2010;11(6):516-25
   PubMed Web of Science ®Google Scholar
• Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38(5):393-414
   PubMed Web of Science ®Google Scholar
• Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000;22(1):118-21
   PubMed Web of Science ®Google Scholar
• Murray M. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents. J Pharm Pharmacol 2006;58(7):871-85
   PubMed Web of Science ®Google Scholar
• Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008;9(5):410-18
   PubMed Web of Science ®Google Scholar
• Latuda (lurasidone HCl) (Prescribing Information). Sunovion Pharmaceutical, Inc. Available from: http://latuda.com/latudaprescribinginformation.pdf. [Last accessed November 2010]
   Google Scholar
• Boulton DW, Kollia G, Mallikaarjun S, Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. Clin Pharmacokinet 2008;47(7):475-85
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Inoue Y, Tateishi T. Determination of a new atypical antipsychotic agent perospirone and its metabolite in human plasma by automated column-switching high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2003;789(2):239-45
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Furukori H, Nakagami T, Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit 2004;26(4):361-5
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. Clin Pharmacol 2004;44(2):179-87
   Google Scholar
• Yokoi F, Grunder G, Biziere K, Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27(2):248-59
   PubMed Web of Science ®Google Scholar
• Mamo D, Graff A, Mizrahi R, Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer pet study. Am J Psychiatry 2007;164:1411-17
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Daniel DG, Carson WH Jr, A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007;41(11):895-905
   PubMed Web of Science ®Google Scholar
• Sekine Y, Ouchi Y, Takei N, Perospirone is a new generation antipsychotic: evidence from a positron emission tomography study of serotonin 2 and D2 receptor occupancy in the living human brain. J Clin Psychopharmacol 2006;26(5):531-3
   PubMed Web of Science ®Google Scholar
• Arakawa R, Ito H, Takano A, Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects. Psychopharmacology (Berl) 2010;209(4):285-90
   PubMed Web of Science ®Google Scholar
• Abilify (Aripiprazole) Tablets: Otsuka Pharmaceutical Co., Ltd. Drug Approval Package.Application no.: 21-436 Clinical Pharmacology Biopharmaceutics Review(S). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-436_abilify.cfm. [Last accessed 4 November 2010]
   Google Scholar
• Caccia S. N-dealkylation of arylpiperazine derivatives: disposition and metabolism of the 1-aryl-piperazines formed. Curr Drug Metab 2007;8(6):612-22
   PubMed Web of Science ®Google Scholar
• Kirschner N, Gemesi LI, Vastag M, In vitro metabolismo of RGH-188. Drug Metab Rev 2008;40: abstract 182
   Web of Science ®Google Scholar
• Meszaros GP, Kapas M, Borsos M, Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic candidate. Eur Neuropsychopharmacol 2007;217(Suppl 4): abstract p.3.c.0.47
   Google Scholar
• Meszaros GP, Agai-Csongor E, Kapas M. Sensitive lc-ms/ms methods for the quantification of rgh-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine. J Pharm Biomed Anal 2008;48(2):388-97
   PubMed Web of Science ®Google Scholar
• Masui T, Kusumi I, Takahashi Y, Koyama T. Effect of carbamazepine on the single oral dose pharmacokinetics of perospirone and its active metabolite. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(7):1330-3
   PubMed Web of Science ®Google Scholar
• Kusumi I, Masui T, Koyama T. Long-term perospirone treatment with a single dose at bedtime in schizophrenia: relevant to intermittent dopamine D2 receptor antagonism. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(2):520-2
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Sawamura K, Ono S, The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(6):830-3
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Tani N, Komuro S, In vitro metabolism of perospirone in rat, monkey and human liver microsomes. Eur J Drug Metab Pharmacokinet 2003;28(1):59-65
   PubMed Web of Science ®Google Scholar
• Kitamura A, Mizuno Y, Natsui K, Characterization of human cytochrome P450 enzymes involved in the in vitro metabolism of perospirone. Biopharm Drug Dispos 2005;26(2):59-65
   PubMed Web of Science ®Google Scholar
• Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-7
   PubMed Web of Science ®Google Scholar
• Grunder G, Fellows C, Janouschek H, Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18f]fallypride pet study. Am J Psychiatry 2008;165(8):988-95
   PubMed Web of Science ®Google Scholar
• Kirschbaum KM, Muller MJ, Malevani J, Serum levels of aripiprazole and dehydroaripiprazole, clinical response, and side effects. World J Biol Psychiatry 2008;9(3):212-8
   PubMed Web of Science ®Google Scholar
• Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006;28(6):744-9
   PubMed Web of Science ®Google Scholar
• Kirschbaum M, Uhr M, Holthoewer D, Pharmacokinetics of acute and sub-chronic aripiprazole in p-glycoprotein deficient mice. Neuropharmacology 2010;59(6):474-9
   PubMed Web of Science ®Google Scholar
• Wood MD, Scott C, Clarke K, Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 2006;546(1-3):88-94
   PubMed Web of Science ®Google Scholar
• Kubo M, Koue T, Inaba A, Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005;20:55-64
   PubMedGoogle Scholar
• Wojnowski L, Kamdem LK. Clinical implications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2006;2(2):171-82
   PubMed Web of Science ®Google Scholar
• Loovers HM, Van Der Weide J. Implementation of CYP2D6 genotyping in psychiatry. Expert Opin Drug Metab Toxicol 2009;5(9):1065-77
   PubMed Web of Science ®Google Scholar
• Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole–dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 2010;71(11):1447-56
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Kusumi I, Ishikane T, Koyama T. In vivo occupation of dopamine D1, D2 and serotonin 2A receptors by novel antipsychotic drug, SM-9018 and its metabolite, in rat brain. J Neural Transm 1998;105(2-3):181-91
   PubMed Web of Science ®Google Scholar
• Masui T, Kusumi I, Takahashi Y, Koyama T. Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit 2006;28(1):73-5
   PubMed Web of Science ®Google Scholar
• Aripiprazole/Abilify (Prescribing Information). Bristol-Myers Squibb, Otsuka Pharmaceutical America, Inc. Rev November 2009. Available from: http://www.abilify.com. [Last accessed October 2010]
   Google Scholar
• Kim JR, Seo HB, Cho JY, Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 2008;66(6):802-10
   PubMed Web of Science ®Google Scholar
• Chiu Y, Nielsen J, Sarrubi D, Kowalski K. Population pharmacokinetics of lurasidone in healthy subjects and subjects with schizophrenia [abstract 1729]. Annual meeting of the population approach group in Europe; 2010. p. 19. Available from: www.page-meeting.org/?
   Google Scholar
• Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J. Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Saf 2006;29(7):587-98
   PubMed Web of Science ®Google Scholar
• Thyssen A, Vermeulen A, Fuseau E, Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders. Clin Pharmacokinet 2010;49(7):465-78
   PubMed Web of Science ®Google Scholar
• Gareri P, De Fazio P, De Fazio S, Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006;23(12):937-56
   PubMed Web of Science ®Google Scholar
• Greenaway M, Elbe D. Focus on aripiprazole: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2009;18(3):250-60
   PubMedGoogle Scholar
• Blankenship K, Erickson CA, Stigler KA, Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6–17 years. Pediatr Health 2010;4(4):375-81
   PubMedGoogle Scholar
• Findling RL, Kauffman RE, Sallee FR, Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol 2008;28(4):441-6
   PubMed Web of Science ®Google Scholar
• Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M, Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 2008;30(4):462-6
   PubMed Web of Science ®Google Scholar
• Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 2005;1(3):447-71
   PubMedGoogle Scholar
• Pichini S, Papaseit E, Joya X, Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit 2009;31(3):283-318
   PubMed Web of Science ®Google Scholar
• Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opin Drug Metab Toxicol 15 March 2011 [Epub ahead of print]
   Google Scholar
• Mallikaarjun S, Shoaf SE, Boulton DW, Bramer SL. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. Clin Pharmacokinet 2008;47(8):533-42
   PubMed Web of Science ®Google Scholar
• Kubo M, Koue T, Maune H, Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007;22(5):358-66
   PubMed Web of Science ®Google Scholar
• Hendset M, Hermann M, Lunde H, Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007;63(12):1147-51
   PubMed Web of Science ®Google Scholar
• Castberg I, Spigset O. Effects of comedication on the serum levels of aripiprazole: evidence from a routine therapeutic drug monitoring service. Pharmacopsychiatry 2007;40(3):107-10
   PubMed Web of Science ®Google Scholar
• Waade RB, Christensen H, Rudberg I, Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009;31(2):233-8
   PubMed Web of Science ®Google Scholar
• Shimakura J, Tani N, Mizuno Y, In vitro drug-drug interactions with perospirone and concomitantly administered drugs in human liver microsomes. Eur J Drug Metab Pharmacokinet 2003;28(1):67-72
   PubMed Web of Science ®Google Scholar
• Wang JS, Zhu HJ, Donovan JL, Aripiprazole brain concentration is altered in p-glycoprotein deficient mice. Schizophr Res 2009;110:90-4
   PubMed Web of Science ®Google Scholar
• Boulton D, Devane C, Liston H, Markowitz J. In vitro p-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci 2002;71(2):163-9
   PubMed Web of Science ®Google Scholar
• Zhou YG, Li KY, Li HD. Effect of the novel antipsychotic drug perospirone on p-glycoprotein function and expression in caco-2 cells. Eur J Clin Pharmacol 2008;64(7):697-703
   PubMed Web of Science ®Google Scholar
• Citrome L. Using oral ziprasidone effectively: the food effect and dose-response. Adv Ther 2009;26(8):739-48
   PubMed Web of Science ®Google Scholar
• Mauri MC, Volonteri LS, Colasanti A, Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46(5):359-88
   PubMed Web of Science ®Google Scholar
• Muscatello MR, Bruno A, Pandolfo G, Emerging treatments in the management of schizophrenia – focus on sertindole. Drug Des Devel Ther 2010;4:187-201
   PubMed Web of Science ®Google Scholar
• Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010;4:33-48
   PubMed Web of Science ®Google Scholar
• De Leon J, Sandson NB, Cozza KL. Apreliminary attempt to personalize risperidone dosing using drug-drug interactions and genetics: part II. Psychosomatics 2008;49(4):347-61
   PubMed Web of Science ®Google Scholar